Bouchalova et al. reported that overexpression of BCL2 is a favorable prognostic marker in triple-negative breast cancer (TNBC) [25] while Ozretic et al. argued that elevated expression of BCL2 is an independent prognostic factor for an unfavorable prognosis in TNBC [26]. Here, BCL2 is linked to triple-negative breast carcinoma.